This retrospective study was approved by the hospital Institutional Review Board. The requirement for written informed consent from patients was waived.
Initially, for the primary cohort, 1091 patients were identified that had undergone a surgical resection or liver transplant for primary HCC between July 2020 and October 2021 at our tertiary care hospital. Patients were included when they had undergone dynamic-enhanced MRI in the liver within 2 months prior to surgery. Exclusion criteria were: (a) preoperative antitumoral treatment; (b) unavailable clinical data; (c) poor quality radiologic or pathologic images; and (d) no pathology slides available for review. Then, 53 patients with a pathologic diagnosis of MTM-HCC and 522 patients with non-MTM HCC were identified. According to the data size of the MTM-HCC group, two months of patients (a total of 70 non-MTM HCC patients) were drawn randomly from the non-MTM HCC group as a control. Finally, 53 patients with MTM-HCC and 70 patients with non-MTM HCC were included (Figure 1
Clinical data were retrospectively collected by reviewing electronic medical records. We collected data on patient demographics and survival; the etiology of chronic liver disease (hepatitis B virus; hepatitis C virus; chronic alcohol consumption; family cancer history; preoperative serum levels of aspartate transaminase, alanine transaminase, albumin, serum ferritin, creatinine, platelets, total bilirubin, and γ-glutamyl transpeptidase; the prothrombin time; alpha-fetoprotein (AFP), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA199), and carcinoembryonic antigen (CEA); and the Barcelona Clinic Liver Cancer stage.
Initially, for the primary cohort, 1091 patients were identified that had undergone a surgical resection or liver transplant for primary HCC between July 2020 and October 2021 at our tertiary care hospital. Patients were included when they had undergone dynamic-enhanced MRI in the liver within 2 months prior to surgery. Exclusion criteria were: (a) preoperative antitumoral treatment; (b) unavailable clinical data; (c) poor quality radiologic or pathologic images; and (d) no pathology slides available for review. Then, 53 patients with a pathologic diagnosis of MTM-HCC and 522 patients with non-MTM HCC were identified. According to the data size of the MTM-HCC group, two months of patients (a total of 70 non-MTM HCC patients) were drawn randomly from the non-MTM HCC group as a control. Finally, 53 patients with MTM-HCC and 70 patients with non-MTM HCC were included (
Clinical data were retrospectively collected by reviewing electronic medical records. We collected data on patient demographics and survival; the etiology of chronic liver disease (hepatitis B virus; hepatitis C virus; chronic alcohol consumption; family cancer history; preoperative serum levels of aspartate transaminase, alanine transaminase, albumin, serum ferritin, creatinine, platelets, total bilirubin, and γ-glutamyl transpeptidase; the prothrombin time; alpha-fetoprotein (AFP), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA199), and carcinoembryonic antigen (CEA); and the Barcelona Clinic Liver Cancer stage.
Free full text: Click here
